Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
09 déc. 2024 16h05 HE
|
OncoCyte Corporation
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings – January 13-16, 2025, San Francisco, CA
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
04 déc. 2024 16h15 HE
|
OncoCyte Corporation
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
02 déc. 2024 16h05 HE
|
OncoCyte Corporation
Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to...
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025
12 nov. 2024 16h05 HE
|
OncoCyte Corporation
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
06 nov. 2024 16h45 HE
|
OncoCyte Corporation
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
16 oct. 2024 16h15 HE
|
OncoCyte Corporation
Oncocyte Announces Participation in the LD Micro Main Event XVII
Conference in Los Angeles
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
08 oct. 2024 08h30 HE
|
OncoCyte Corporation
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO...
Oncocyte Signs Leading Transplant Centers in US and Germany
02 oct. 2024 18h41 HE
|
OncoCyte Corporation
GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volumeCompany clears first stage gate in clinical product development process and has...
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
02 oct. 2024 18h35 HE
|
OncoCyte Corporation
IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a...
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
12 août 2024 16h10 HE
|
OncoCyte Corporation
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study